These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31831868)

  • 1. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
    Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
    Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR
    Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
    Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
    Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
    Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
    Chatterjee S; Majumder A; Ray S
    Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
    Ratner RE; Parikh S; Tou C;
    Diab Vasc Dis Res; 2007 Sep; 4(3):214-21. PubMed ID: 17907111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
    Balakumar P; Mahadevan N; Sambathkumar R
    Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
    Rodriguez-Gutierrez R; González JG; Parmar D; Shaikh F; Cruz-López P
    J Lipid Res; 2022 Jul; 63(7):100233. PubMed ID: 35605678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
    Wilding JP; Gause-Nilsson I; Persson A;
    Diab Vasc Dis Res; 2007 Sep; 4(3):194-203. PubMed ID: 17907109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
    Deshpande A; Toshniwal H; Joshi S; Jani RH
    PLoS One; 2016; 11(1):e0146222. PubMed ID: 26789842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
    Digenio A; Dunbar RL; Alexander VJ; Hompesch M; Morrow L; Lee RG; Graham MJ; Hughes SG; Yu R; Singleton W; Baker BF; Bhanot S; Crooke RM
    Diabetes Care; 2016 Aug; 39(8):1408-15. PubMed ID: 27271183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
    Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
    Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
    Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.